Monte Carlo simulation for evaluation of the efficacy of carbapenems and new quinolones against ESBL-producing Escherichia coli

Bush, 1995, A functional classification scheme for beta-lactamases and its correlation with molecular structure, Antimicrob Agents Chemother, 39, 1211, 10.1128/AAC.39.6.1211 Paterson, 2004, International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum betalactamase production in nosocomial infections, Ann Intern Med, 140, 26, 10.7326/0003-4819-140-1-200401060-00008 Winokur, 2001, Variations in the prevalence of strains expressing an extended-spectrum betalactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region, Clin Infect Dis, 32, 94, 10.1086/320182 Wiener, 1999, Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes, JAMA, 281, 517, 10.1001/jama.281.6.517 Colodner, 2004, Risk factors for the development of extended-spectrum betalactamase-producing bacteria in nonhospitalized patients, Eur J Clin Microbiol Infect Dis, 23, 163, 10.1007/s10096-003-1084-2 Pitout, 2004, Populationbased laboratory surveillance for Escherichia coli-producing extended-spectrum beta-lactamases: importance of community isolates with blaCTX-M genes, Clin Infect Dis, 38, 1736, 10.1086/421094 Craig, 1998, Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men, Clin Infect Dis, 26, 1, 10.1086/516284 Nakashima, 2005, Phase I study of doripenem, a new carbapenem antibiotic for injection in healthy volunteers, Chemotherapy, 53, 104 Saito, 1994, Pharmacokinetic study on biapenem, Chemotherapy, 42, 277 Saito, 1985, Studies on imipenem/cilastatin sodium (MK-0787/MK-0791), Chemotherapy, 33, 379 Saito, 1992, Pharmacokinetic study on meropenem, Chemotherapy, 40, 276 Kobayashi, 1985, Phase I study with BAY o 9867(cipro-floxacin), Chemotherapy, 33, 140 Nakajima, 1999, Phase 1 study of gatifloxacin, new quinolone, Chemotherapy, 48, 175 Nakajima, 1999, Phase 1 clinical study of pasufloxacin mesilate, Jpn J Chemotherapy, 47, 175 Okuyama, 1997, Pharmacokinetics of prulifloxacin. First communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration, Arzneimittelforschung, 47, 276 Okazaki, 1991, Enantioselective disposition of ofloxacin in humans. Antimicrob, Agents Chemother, 35, 2106, 10.1128/AAC.35.10.2106 2005 Paterson, 2004, Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases, Clin Infect Dis, 39, 31, 10.1086/420816 Kuti, 2004, Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002, Antimicrob Agents Chemother, 48, 2464, 10.1128/AAC.48.7.2464-2470.2004 Craig, 2001, Does the dose matter?, Clin Infect Dis, 33, 233, 10.1086/321854 Forrest, 1993, Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob, Agents Chemother, 37, 1073, 10.1128/AAC.37.5.1073 Moczygemba, 2004, Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases, Clin Ther, 26, 1800, 10.1016/j.clinthera.2004.11.009